Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Fulcrum Therapeutics Inc
FULC
Healthcare
Biotechnology
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. The Company’s clinical product candidate, losmapimod, is developed for the potential treatment of facioscapulohumeral muscular dystrophy (FSHD). Its other clinical product candidate is FTX...
-6058, which is developed for the treatment of certain hemoglobinopathies, including sickle cell disease (SCD). In addition to product candidate development, the Company has developed a drug discovery approach that it employs to systematically identify and validate cellular drug targets that can potentially modulate gene expression to treat known root causes of genetically defined rare diseases. The Company has developed pociredir, which is designed to elevate the level of fetal hemoglobin, or HbF, for the treatment of people with SCD.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:FULC)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
Next
(0)
•••
PressRelease
X
Post by
PressRelease
on Sep 29, 2024 8:02pm
New Press Release - Fulcrum Therapeutics, Inc. Is Being Investigated For Securities Law Violations And The Schall Law Firm Invites Shareholders With Losses To Help
LOS ANGELES, CA / ACCESSWIRE / September 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company") (NASDAQ:FULC) for violations of the securities laws...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Sep 28, 2024 9:19pm
New Press Release - Levi & Korsinsky Announces an Investigation on Behalf of Fulcrum Therapeutics, Inc. (FULC) Shareholders Who May Have Been Affected by Fraud
NEW YORK, NY / ACCESSWIRE / September 28, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics, Inc.") (NASDAQ:FULC) concerning possible violations of federal securities laws.Fulcrum announced on September 12, 2024,...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Sep 28, 2024 8:18pm
New Press Release - The Schall Law Firm Is Looking Into Whether Fulcrum Therapeutics Inc Committed Securities Fraud And Impacted Investors Should Reach Out
LOS ANGELES, CA / ACCESSWIRE / September 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company") (NASDAQ:FULC) for violations of the securities laws...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Sep 27, 2024 7:03pm
New Press Release - Levi & Korsinsky Reminds Shareholders of an Investigation into Fulcrum Therapeutics, Inc. (FULC) Regarding Potential Securities Fraud Allegations
NEW YORK, NY / ACCESSWIRE / September 27, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics, Inc.") (NASDAQ:FULC) concerning possible violations of federal securities laws.Fulcrum announced on September 12, 2024,...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Sep 27, 2024 6:37pm
New Press Release - Shareholders Are Encouraged To Join The Schall Law Firm's Inquiry Into Fulcrum Therapeutics, Inc. For Violating Securities Laws
LOS ANGELES, CA / ACCESSWIRE / September 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company") (NASDAQ:FULC) for violations of the securities laws...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Sep 27, 2024 1:31pm
New Press Release - FULC ALERT - Levi & Korsinsky Has Commenced an Investigation on Behalf of Fulcrum Therapeutics, Inc. Shareholders Who Lost Money
NEW YORK, NY / ACCESSWIRE / September 27, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics, Inc.") (NASDAQ:FULC) concerning possible violations of federal securities laws.Fulcrum announced on September 12, 2024,...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Sep 27, 2024 10:03am
New Press Release - Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Fulcrum Therapeutics, Inc. (FULC) And Encourages Shareholders to Reach Out
NEW YORK, NY / ACCESSWIRE / September 27, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company") (NASDAQ:FULC). Investors who purchased Fulcrum securities are encouraged to obtain additional...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Sep 26, 2024 7:03pm
New Press Release - ATTENTION Fulcrum Therapeutics, Inc. Investors: You May Have Been Affected by Fraud- Contact Levi & Korsinsky to Discuss Your Rights
NEW YORK, NY / ACCESSWIRE / September 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics, Inc.") (NASDAQ:FULC) concerning possible violations of federal securities laws.Fulcrum announced on September 12, 2024,...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Sep 26, 2024 6:41pm
New Press Release - Fulcrum Therapeutics Inc Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Investors To Lend A Hand
LOS ANGELES, CA / ACCESSWIRE / September 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company") (NASDAQ:FULC) for violations of the securities laws...
read article.
(303)
•••
whytestocks
X
Post by
whytestocks
on Sep 26, 2024 10:31am
Bronstein, Gewirtz & Grossman, LLC Announces an Investigatio
NEWS: $FULC Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Fulcrum Therapeutics, Inc. (FULC) and Encourages Shareholders to Learn More About the InvestigationNEW YORK, NY
...more
(0)
•••
PressRelease
X
Post by
PressRelease
on Sep 26, 2024 10:17am
New Press Release - Levi & Korsinsky Announces an Investigation on Behalf of Fulcrum Therapeutics, Inc. (FULC) Shareholders Who May Have Been Affected by Fraud
NEW YORK, NY / ACCESSWIRE / September 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics, Inc.") (NASDAQ:FULC) concerning possible violations of federal securities laws.Fulcrum announced on September 12, 2024,...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Sep 26, 2024 10:12am
New Press Release - Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Fulcrum Therapeutics, Inc. (FULC) and Encourages Shareholders to Learn More About the Investigation
NEW YORK, NY / ACCESSWIRE / September 26, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company") (NASDAQ:FULC). Investors who purchased Fulcrum securities are encouraged to obtain additional...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Sep 25, 2024 8:05pm
New Press Release - Shareholders that lost money on Fulcrum Therapeutics, Inc. (FULC) should contact Levi & Korsinsky about Securities Fraud Investigation - FULC
NEW YORK, NY / ACCESSWIRE / September 25, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics, Inc.") (NASDAQ:FULC) concerning possible violations of federal securities laws.Fulcrum announced on September 12, 2024,...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Sep 25, 2024 7:46pm
New Press Release - The Schall Law Firm Is Looking Into Fulcrum Therapeutics, Inc. For Possible Securities Law Violations And Shareholders Are Invited To Participate
LOS ANGELES, CA / ACCESSWIRE / September 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company") (NASDAQ:FULC) for violations of the securities laws...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Sep 25, 2024 4:22pm
New Press Release - Levi & Korsinsky Announces an Investigation on Behalf of Fulcrum Therapeutics, Inc. (FULC) Shareholders Who May Have Been Affected by Fraud
NEW YORK, NY / ACCESSWIRE / September 25, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics, Inc.") (NASDAQ:FULC) concerning possible violations of federal securities laws.Fulcrum announced on September 12, 2024,...
read article.
Prev
1
2
3
4
5
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Creating a Non-Opioid Solution for Chronic Pain Management
Tribe Announces Preliminary Q4-2024 Results, Achieving Positive Adjusted EBITDA and Increased Revenue Run-Rate